Revance Therapeutics, Inc. (RVNC)

Last Closing Price: 3.02 (2024-05-17)

Net Income (Quarterly)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Revance Therapeutics, Inc. (RVNC) had Net Income of $-53.15M for the most recently reported fiscal quarter, ending 2024-03-31.

Figures for fiscal quarter ending 2024-03-31
Income Statement Financials
$51.94M
Net Income
$-53.15M
$14.91M
$37.02M
$98.76M
$-46.83M
$-2.70M
$-49.52M
$-49.52M
$-49.52M
$-49.52M
$-53.15M
$-49.52M
$-46.83M
$-45.45M
91.92M
91.92M
$-0.58
$-0.58
Balance Sheet Financials
$369.69M
$17.50M
$138.43M
$508.12M
$68.90M
$424.84M
$537.89M
$606.79M
$-98.67M
$-107.40M
$-98.67M
104.41M
Cash Flow Statement Financials
$-65.94M
$-31.71M
$92.83M
$144.75M
$139.93M
$-4.82M
$8.99M
--
--
Fundamental Metrics & Ratios
5.37
--
--
1.30
-4.36
71.29%
-90.16%
-90.16%
--
-95.36%
-102.34%
$-67.65M
--
--
--
0.10
0.30
1.74
51.79
50.19%
46.11%
-9.75%
-15.18%
$-0.95
$-0.74
$-0.72